These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 26844273)
1. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. Zhang Y; Wang X; Qin X; Wang X; Liu F; White E; Zheng XF EBioMedicine; 2015 Dec; 2(12):1944-56. PubMed ID: 26844273 [TBL] [Abstract][Full Text] [Related]
2. Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer. Lee HS; Lee S; Cho KH Int J Cancer; 2020 Nov; 147(10):2824-2837. PubMed ID: 32599680 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
4. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063 [TBL] [Abstract][Full Text] [Related]
5. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo. Zhang J; Jiang W; Liu W; Wu JJ; Song L; Cheng JX; Yao M; Yang LP; Yao DF Future Oncol; 2016 Feb; 12(4):515-24. PubMed ID: 26776341 [TBL] [Abstract][Full Text] [Related]
6. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo. Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656 [TBL] [Abstract][Full Text] [Related]
7. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225 [TBL] [Abstract][Full Text] [Related]
8. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911 [TBL] [Abstract][Full Text] [Related]
10. Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancer. Qin X; Wang X; Liu F; Morris LE; Wang X; Jiang B; Zhang Y Cancer Lett; 2016 Jun; 376(1):83-94. PubMed ID: 26975632 [TBL] [Abstract][Full Text] [Related]
11. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401 [TBL] [Abstract][Full Text] [Related]
12. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600. Wu L; Zhang J; Wu H; Han E Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179 [TBL] [Abstract][Full Text] [Related]
13. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297 [TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811 [TBL] [Abstract][Full Text] [Related]
16. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. Lu M; Zessin AS; Glover W; Hsu DS PLoS One; 2017; 12(1):e0169439. PubMed ID: 28060954 [TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma. Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658 [TBL] [Abstract][Full Text] [Related]
18. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation. Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235 [TBL] [Abstract][Full Text] [Related]
19. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118 [TBL] [Abstract][Full Text] [Related]
20. Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. Lipner MB; Marayati R; Deng Y; Wang X; Raftery L; O'Neil BH; Yeh JJ PLoS One; 2016; 11(1):e0147113. PubMed ID: 26760500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]